持续报名中：2025第三届中国整形外科创新转化大赛 验证中心项目启动会 | 动物实验与创业 | 医疗器械创新（广州） | 医美行业交流（苏州） | 医美行业交流 （上海）| 化妆品原料研讨（广州） | 药用植物与美容 | 家用美容仪 ｜ 医美新材料：琼脂糖&羟基磷灰 石 | 医美光电设备交流：国产超声刀、热玛吉 ｜注射类医美投资趋势与市场机遇 ｜ 医美疤痕修复产品 与创新趋势交流会 成果路演：八大处整形医院专场推介项目大全 第二届八大处整形美容产业论坛 | 第二届整形外科创新转化大赛 | 医美投资分论坛 | 注册与申报分论坛 | 临床研究分论坛 皮肤作为人体最大的器官，在创伤、慢性病与医疗美容等多种情境中，其修复效率 始终是 临床与工程交叉研究 的重点。近年来， 外泌体与水凝胶 的结合，正在成为 促进皮肤组织再生与精准修复的关键技术路径。 外泌体 具备良好的生物活性与信号调控功能， 水凝胶 则以其高度的生物相容性与 可控递送能力，成为理想的 "智能载体" 。这两类技术的融合，正为 慢性创面、术 后修复、医美损伤干预 等应用场景带来新的材料解决方案。 本次活动，我们特别邀请在该方向深耕多年的 北京航空航天大学医 ...

Group 1 - The core viewpoint of the article is that Tianyuan Home Elderly Care Industry Group has successfully completed a multi-million A-round financing to enhance its AI intelligent ecosystem and expand into key cities [1][3] Group 2 - Tianyuan Home Elderly Care Industry Group was established in December 2015 and is headquartered in Beijing, focusing on home elderly care services as a comprehensive service institution [3] - The company has pioneered an integrated online and offline elderly care service model, providing 24-hour dedicated community service, emergency rescue within 15 minutes, and a variety of one-stop services [3] - Currently, Tianyuan Home operates 30 service stations, 1 elderly care station, 1 senior club, and 1 suburban travel base, showcasing its extensive service network [3] - The core product of Tianyuan Home is the integrated smart elderly care service system, which combines online platforms with offline service resources to offer diverse services such as emergency rescue, medical assistance, and home safety checks [3] - The company leverages intelligent service process management, efficient resource allocation, and precise user demand response, positioning itself as a leader in the trillion-dollar elderly care market [3]

Core Viewpoint - The article highlights the advancements in breast ultrasound technology through the introduction of Smart Breast, an AI-assisted feature by Mindray, aimed at improving diagnostic efficiency and accuracy in breast imaging [2][4]. Group 1: Smart Breast Technology - Smart Breast utilizes deep learning algorithms trained on a large dataset of breast ultrasound images to perform automatic lesion detection and segmentation [3]. - The technology shows high sensitivity (92%) and specificity (85%) in detecting breast masses, outperforming traditional manual ultrasound analysis [4]. - Smart Breast is particularly effective in dense breast tissue, increasing the likelihood of detecting small lesions (<1 cm) [4]. Group 2: Clinical Impact - Clinical feedback indicates that Smart Breast can reduce ultrasound examination time by approximately 30%, making it especially useful for radiologists in high-volume breast screening [4]. - The system can intelligently identify suspicious lesions, automatically delineate their boundaries, and measure key parameters, aiding in disease progression monitoring and surgical planning [6]. Group 3: Company Overview - Mindray Medical, founded in 1991 and headquartered in Shenzhen, is a leading global medical device supplier with a diverse product range including patient monitoring, in-vitro diagnostics, and medical imaging systems [5]. - In 2024, Mindray reported an annual revenue of 36.73 billion yuan, a year-on-year increase of 5.1%, with a net profit of 11.67 billion yuan, reflecting a 0.7% growth [5].

Core Viewpoint - The article discusses the approval and significance of the V-Clip® left atrial appendage closure system developed by Beijing Lingjian Medical Technology Co., Ltd., highlighting its innovative design and clinical benefits in reducing stroke risk for patients with atrial fibrillation [2][4][10]. Industry Background - The left atrial appendage (LAA) is a significant source of thrombus formation in patients with atrial fibrillation, and its closure can reduce the risk of ischemic stroke by 33% according to a study published in the New England Journal of Medicine [5][7]. - Current guidelines increasingly recommend LAA intervention during cardiac surgery for atrial fibrillation patients, indicating a growing recognition of its importance in stroke prevention [7]. Product Introduction - The V-Clip® is the first V-shaped single-end opening closure device approved in China and the third globally, featuring a design that optimizes the capture and closure of the LAA [4][10]. - Clinical studies show a 100% success rate in LAA closure with no adverse events related to the device, aligning with the highest recommendation level in current guidelines for atrial fibrillation surgery [11]. Competitor Analysis - Other approved LAA closure systems in China include the C-Clip series by Beijing Maidi Top Medical Technology Co., Ltd. and the PerClip system by Puhui Biomedical Engineering Co., Ltd., indicating a competitive landscape in the LAA closure market [16][20]. - The C-Clip® series is noted for being the first LAA closure product approved through the "innovative green channel" in China, showcasing its significance in the market [17][18]. Company Overview - Lingjian Medical was established in 2018 and focuses on the research, development, production, and sales of advanced cardiovascular medical devices, positioning itself as a key player in the industry [23].

招商通知： 第三届全球手术机器人大会 2025 年 7 月 3 日， 财政部 发布《财政部关于在政府采购活动中对自欧盟进口的医疗器械采取相关措施的通知》（财库〔2025〕19 号）。 该通知自 2025 年 7 月 6 日 起正式施行。 本次通知针对部分自欧盟进口的医疗器械，在政府采购中作出限制，文件明确涉及采购预算金额、产品范围、以及在华欧资企业等多个关键要素。 # 政策核心内容 根据《通知》内容，核心要求包括以下几方面： 通知随文发布了《具体品目清单》，列明受影响的产品范围。 通知明确， 此次限制措施不适用于在中国境内生产的欧资企业产品。 即在华欧资企业，其在中国境内生产并获得相应注册和生产资质的医疗器械产品，不在此次 限制之列，仍可正常参与政府采购项目。 这一条款保证了在华欧资企业正常的本土化经营，也避免了对中国现有医疗供应链的过度冲击。 # 政策背景：对 等回 应与贸易环 境 近年来，欧盟针对中国医疗器械产品采取了多项市场准入、合规及供应链监管措施。例如： 预算门槛 ：针对采购预算在 4500 万元人民币 及以上的医疗器械政府采购项目。 排除欧盟企业 ：若采购人确需采购进口产品，履行法定程序后，应当排 ...

这与 Brainlab 一贯的经营风格一致。作为一家深耕全球高端医疗器械市场的企业，Brainlab 多年来始终保持稳健的现金流。公司特别强调， 即便取消 IPO， Brainlab 的资金实力仍足以支持未来的有机增长，无需急于依赖外部融资。 招商通知： 第三届全球手术机器人大会 2025年7月，德国医疗科技领军企业 博医来Brainlab 宣布 推迟其原定在法兰克福证券交易所的首次公开募股（IPO）计划。 虽然此次 IPO 已获得市场超额认 购，反响颇为积极，但 Brainlab 管理层在审慎考量后，仍决定按下"暂停键"。 这家在神经外科手术导航领域拥有全球60%市场份额、被誉为"手术导航金标准"的创新型企业，在行业动荡与地缘政治风险的背景下，展现出对技术主导型企 业未来发展节奏的深刻把握。 # 超额认 购背后，却选择 谨 慎 根据 Brainlab 此前提交的招股文件，公司原计划发行 200 万股新股，并转让最多 320 万股现有股份，拟募集约 4.16 亿欧元（折合人民币超 30 亿元），定价区 间为每股 80-100 欧元。按最高发行价计算，Brainlab 的估值可达 17 亿欧元（约合人民币 14 ...

Core Viewpoint - The medical robotics industry has entered a complex phase by 2025, with evolving product forms, clearer clinical pathways, and a more rational capital environment, emphasizing the need for a comprehensive ecosystem [1]. Group 1: Event Overview - The Third Global Surgical Robotics Conference will take place from September 4 to 6, 2025, in Beijing, focusing on the theme "MedRobot Next: The Future of Technology" [2]. - The conference serves as a platform for discussing technological advancements, supply chain transformations, hospital system upgrades, and international trends in the surgical robotics field [1][2]. Group 2: Key Themes and Discussions - The conference will cover various topics, including the evolution of technical systems and intelligent advancements, commercialization and hospital system implementation, and global strategies for market expansion [4][5][6]. - A special session will focus on the integration of clinical needs into engineering goals, highlighting the importance of collaboration between medical and engineering fields [7]. Group 3: Technological Trends - The next generation of surgical robots will emphasize AI integration to enhance autonomy and system collaboration efficiency, alongside challenges in integrating robotic systems with hospital infrastructures [8]. - The commercial pathways for surgical robots will be analyzed through global market comparisons and experience extraction, addressing procurement decision-making processes from equipment to system evaluations [8]. Group 4: Supply Chain and Ecosystem - The conference will explore the complete medical robotics industry chain, including opportunities and bottlenecks in domestic core components, and best practices for supply chain collaboration [13][9]. - Discussions will also focus on the importance of training systems, maintenance frameworks, and remote support in defining the boundaries of ecosystem value [13]. Group 5: Industry Recognition - The MedRobot annual awards have become one of the most recognized technology awards in China's medical robotics sector, providing insights into how technology is reshaping medical systems [14]. - The event aims to identify sustainable and collaborative future technology partners through multi-dimensional discussions among manufacturers, component suppliers, algorithm companies, and clinical teams [14].

Core Insights - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University [1][5]. Course Highlights - The workshop aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [5]. - Participants will learn the complete path from concept to market for medical devices, addressing the common issue of collaboration between medical professionals and engineering teams [5]. Target Audience - The program is suitable for various professionals including doctors, medical technicians, engineering personnel from research institutions, industry practitioners, investors, and entrepreneurs interested in medical device innovation [6][10]. Training Information - The workshop will take place over two days on August 16-17, 2025, at Shanghai Jiao Tong University [6][10]. - The fee for participation is 8999 yuan per person, which includes course materials and refreshments, while accommodation is self-arranged [10]. Course Structure - The first day focuses on medical innovation and technology layout, including practical exercises and team drills to foster interdisciplinary communication [7][9]. - The second day will cover innovation commercialization and team building, emphasizing key points in medical engineering innovation and funding sources [13][16]. Expert Faculty - The faculty includes leading experts from Shanghai Jiao Tong University with extensive experience in medical technology and investment, providing insights into successful case studies and best practices in medical innovation [14][17]. Additional Opportunities - Participants will have the chance to network with industry experts, showcase their projects, and explore potential investment and collaboration opportunities [6][11].

Core Viewpoint - The second Global Medical Technology Conference will be held on July 17, 2025, in Beijing, focusing on "Cutting-edge Technology: From R&D to Clinical Application" [1][6]. Group 1: Conference Overview - The conference will take place at the Zhongguancun Exhibition Center in Haidian District, Beijing [6]. - The expected attendance is approximately 500 participants, including representatives from government, hospitals, leading enterprises, startups, investment institutions, and research institutes [8]. - The agenda will include discussions on product innovation, technology implementation, and medical-engineering collaboration [6][8]. Group 2: Key Topics of Discussion - The conference will explore challenges in the implementation of medical AI and large models, including multi-modal data integration and embedding into physician workflows [9]. - Topics will also cover advancements in imaging equipment and platform upgrades, high-value consumables, energy systems, and material innovations [10][11][12][13]. - A roundtable discussion will focus on how innovative products can effectively enter clinical settings and be utilized [14]. Group 3: Participation and Opportunities - Companies are encouraged to participate for brand exposure and business collaboration opportunities [1]. - Registration can be completed via a provided link or QR code [15].

Group 1 - The article discusses a training program for future leaders in the healthcare industry, focusing on strategic diagnosis and execution [2] - The program is scheduled to take place from July 11 to July 13 at two locations: Fujifilm Smart Medical Technology Training Center and Shanghai Jiao Tong University School of Medicine [2] - The agenda includes a workshop on corporate strategy and value engines led by Zhang Xiaopeng, who has extensive experience in healthcare management and leadership roles [5] Group 2 - On July 12, a workshop titled "Corporate Strategic Decision-Making and Growth Dilemmas Across Cycles" will be conducted by Zhang Landing, who has nearly 30 years of corporate management experience [6] - Zhang Landing is the chairman of Xiya Equity Investment Fund Management and has served as an independent director for several listed companies [6] - Participants interested in the course are encouraged to fill out a form to provide their basic information for further contact [6]